Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma

Fig. 1

Distribution of the ordinal COVID-19 severity outcome, stratified by modality of anti-cancer therapy received within 3 months prior to COVID-19 diagnosis. Note: The ordinal COVID-19 severity outcome was based on a patient’s most severe reported disease status during follow-up (for example, a patient who was hospitalized and later died is included in “Died”). The width of the boxes is proportional to the number of patients who received each anti-cancer therapy; the height of the boxes is proportional to the number of patients in each outcome level. Patient numbers are listed for each outcome level

Back to article page